COGT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
102.6M
-0.9%
103.6M
+4.1%
99.5M
+19.4%
83.4M
+10.3%
75.6M
R&D
70.8M
-6.0%
75.4M
-0.3%
75.6M
+9.5%
69.0M
+10.9%
62.2M
SG&A
31.8M
+12.7%
28.2M
+18.0%
23.9M
+66.6%
14.4M
+7.4%
13.4M
Operating Income
-102638000
+0.9%
-103607000
-4.1%
-99493000
-19.4%
-83355000
-10.3%
-75582000
EBITDA
-101897000
+1.1%
-102981000
-4.2%
-98865000
-19.5%
-82714000
-10.4%
-74927000
Net Income
-96405000
+1.0%
-97352000
+5.0%
-102492000
-26.6%
-80930000
-10.1%
-73529000
EPS (Basic)
$-0.52
+1.9%
$-0.53
+10.2%
$-0.59
-18.0%
$-0.50
+5.7%
$-0.53
EPS (Diluted)
$-0.52
+1.9%
$-0.53
+10.2%
$-0.59
-18.0%
$-0.50
+5.7%
$-0.53
Shares (Diluted)
171.0M
+5.4%
162.2M
+7.9%
150.3M
+9.2%
137.6M
+20.2%
114.5M
Cogent Biosciences (COGT) โ€” Financials